NIAID renews funding for the Adult AIDS Clinical Trials Group

December 21, 1999

The National Institute of Allergy and Infectious Diseases (NIAID) has renewed funding for the Adult AIDS Clinical Trials Group (AACTG), the largest clinical trials network in the world. Under the new award, the AACTG will receive $80 million in the first year of a five-year grant. The funding enables the network to continue conducting studies of antiviral interventions, methods to reconstitute the immune system damaged by HIV, and the treatment and prevention of opportunistic diseases and other HIV-related complications.

"Since the beginning of the AIDS epidemic, the AACTG has made enormous contributions in helping people with HIV live dramatically longer and healthier lives," says NIAID Director Anthony S. Fauci, M.D. "AACTG studies have been and will continue to be an invaluable source of scientific data, significantly advancing our ability to treat HIV."

The AACTG consists of a Coordinating and Operations Center, Statistical and Data Analysis Center and 32 AIDS Clinical Trials Units across the country, including new sites in Texas, Tennessee, Pennsylvania, Rhode Island and New York. Chair Robert T. Schooley, M.D., and Vice Chair Constance A. Benson, M.D., of the University of Colorado Health Sciences Center in Denver, will continue to provide the group's executive leadership. Victor DeGruttola, Sc.D., of the Harvard School of Public Health in Boston, will continue to direct the Statistical and Data Analysis Center.

"With a very strong group of internationally recognized and dedicated HIV researchers, the AACTG has remained on the cutting edge of HIV therapeutics and responded rapidly to new scientific opportunities," says Dr. Schooley. Acknowledging the AACTG's effectiveness in turning laboratory discoveries into new intervention strategies at the bedside, peer reviewers rated the network as "outstanding." From its start in 1987, the AACTG has played a pivotal role in defining the standard of care for adults infected with HIV. AACTG trials have evolved from early studies with single-drug regimens to the current drug "cocktails" that make up highly active antiretroviral therapy, or HAART. Other recent AACTG studies have Among the future priorities for the AACTG are defining the most effective antiretroviral treatment strategies at each stage of HIV infection, developing new ways to prevent or treat opportunistic infections, and focusing on the growing problem of hepatitis C co-infection with HIV disease. Researchers also will study the interaction between various anti-HIV drugs and seek to lessen metabolic abnormalities and other side effects associated with HAART.

Developing strategies to eliminate reservoirs where HIV lingers within the body will be another important focus. Network clinicians will explore new approaches to augment the immune system in the presence of HIV and will examine promising leads into restoring immune function. The long-term effects of anti-HIV therapeutics will be further scrutinized as the AACTG seeks to improve patients' abilities to tolerate these therapies.

***BACKGROUND***

The AACTG is an outgrowth of NIAID's first major program to evaluate potential treatments for people with AIDS, which began in the summer of 1986. In 1996, the original AIDS Clinical Trials Group branched into two separate programs, the Adult AIDS Clinical Trials Group and the Pediatric AIDS Clinical Trials Group (PACTG). Since 1986, more than 50,000 volunteers have enrolled in AACTG studies, and almost 18,000 children and pregnant women have participated in PACTG studies.

NIAID supports a broad program in HIV therapeutic research. This ranges from basic laboratory science to bench-to-bedside studies, which test new approaches in small numbers of people, to larger clinical trials that recruit patients throughout the country to evaluate the best new ways to treat and manage HIV disease. In addition to the AACTG and the PACTG, other NIAID-sponsored therapeutic research programs include the Acute Infection and Early Disease Research Program, the Terry Beirn Community Program for Clinical Research on AIDS, and the Integrated Preclinical/Clinical Therapeutics Research Program.

******************************************************
AACTG ADULT CLINICAL TRIALS UNITS AND PRINCIPAL INVESTIGATORS

ALABAMA
*University of Alabama at Birmingham - Michael S. Saag, M.D.

CALIFORNIA
*Stanford University - Thomas C. Merigan, Jr., M.D. *University of California Los Angeles - Ronald T. Mitsuyasu, M.D. *University of California San Diego - Diane Havlir, M.D. *University of California San Francisco - Mark Jacobson, M.D. *University of Southern California Medical Center - John M. Leedom, M.D.

COLORADO
*University of Colorado Health Sciences Center - Robert T. Schooley, M.D.

FLORIDA
*University of Miami School of Medicine - Margaret A. Fischl, M.D.

HAWAII
*University of Hawaii - Cecila M. Shikuma, M.D.

ILLINOIS
*Northwestern University - Robert L. Murphy, M.D.

INDIANA
*Indiana University - Joseph L. Wheat, M.D.

MARYLAND
*Johns Hopkins University School of Medicine - John G. Bartlett, M.D.

MASSACUSSETTS
*Harvard Medical School - Martin S. Hirsch, M.D.

MINNESOTA
*University of Minnesota Medical School - Henry H. Balfour, Jr., M.D.

MISSOURI
*Washington University - William G. Powderly, M.D.

NEW YORK
*Beth Israel Medical Center - Donna Mildvan, M.D. *Columbia University - Scott M. Hammer, M.D. *New York University Medical Center - Fred T. Valentine, M.D. *University of Rochester Medical Center - Richard C. Reichman, M.D.

NORTH CAROLINA
*Duke University - John A. Bartlett, M.D. *University of North Carolina at Chapel Hill - Charles M. van der Horst, M.D.

OHIO
*Case Western Reserve University - Michael M. Lederman, M.D. *Ohio State University Medical Center - Robert J. Fass, M.D. *University of Cincinnati - Judith T. Feinberg, M.D.

PENNSYLVANIA
*University of Pennsylvania - Harvey M. Friedman, M.D. *University of Pittsburgh - John W. Mellors, M.D.

RHODE ISLAND
*The Miriam Hospital - Timothy P. Flanigan, M.D.

TENNESSEE
*Vanderbilt University School of Medicine - David W. Haas, M.D.

TEXAS
*University of Texas Medical Branch - Richard B. Pollard, M.D. *University of Texas Southwestern Medical Center - Richard A. Koup, M.D.

WASHINGTON
*University of Washington - Ann C. Collier, M.D.

PUERTO RICO
*University of Puerto Rico School of Medicine - Jorge L. Santana, M.D.
-end-
Press release, fact sheets and other NIAID materials are available on the NIAID web site at www.niaid.nih.gov.

NIH/National Institute of Allergy and Infectious Diseases

Related Immune System Articles from Brightsurf:

How the immune system remembers viruses
For a person to acquire immunity to a disease, T cells must develop into memory cells after contact with the pathogen.

How does the immune system develop in the first days of life?
Researchers highlight the anti-inflammatory response taking place after birth and designed to shield the newborn from infection.

Memory training for the immune system
The immune system will memorize the pathogen after an infection and can therefore react promptly after reinfection with the same pathogen.

Immune system may have another job -- combatting depression
An inflammatory autoimmune response within the central nervous system similar to one linked to neurodegenerative diseases such as multiple sclerosis (MS) has also been found in the spinal fluid of healthy people, according to a new Yale-led study comparing immune system cells in the spinal fluid of MS patients and healthy subjects.

COVID-19: Immune system derails
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.

Immune cell steroids help tumours suppress the immune system, offering new drug targets
Tumours found to evade the immune system by telling immune cells to produce immunosuppressive steroids.

Immune system -- Knocked off balance
Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune diseases and allergies.

Too much salt weakens the immune system
A high-salt diet is not only bad for one's blood pressure, but also for the immune system.

Parkinson's and the immune system
Mutations in the Parkin gene are a common cause of hereditary forms of Parkinson's disease.

How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.

Read More: Immune System News and Immune System Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.